Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: Tumour direct priming

Immunology

Volumn 128, Issue 3, 2009, Pages 420-428

  Li, Xiao Lin ^a   Zhang, Dongqing ^b   Knight, David ^a   Odaka, Yoshinobu ^a   Glass, Jonathan ^c   Mathis, J Michael ^a,c   Zhang, Qian Jin ^a,c  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

B7.1; T cells; Transporter associated with antigen processing; Tumour immunity

Indexed keywords

TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B7.1 GENE; CELL LYSATE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; FEMALE; GENE; GENE EXPRESSION; H 2KB GENE; IMMUNE RESPONSE; IMMUNIZATION; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIGENS, CD80; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, LEWIS LUNG; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; H-2 ANTIGENS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; TRANSFECTION; TRANSGENES;

EID: 70349678946     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03127.x     Document Type: Article

References (40)

1. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004 19 : 216 224. (Pubitemid 39481937)
2. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumors on. Immunol Today 1997 18 : 292 299.
3. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000 21 : 455 464.
4. Wolpert EZ, Petersson M, Chambers BJ, Sandberg JK, Kiessling R, Ljunggren HG, Karre K. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci USA 1997 94 : 11496 11501.
5. De Silva AD, Boesteanu A, Song R, Nagy N, Harhaj E, Harding CV, Joyce S. Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides. J Immunol 1999 163 : 4413 4420.
6. Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 2000 18 : 515 520.
7. van Hall T, Wolpert EZ, van Veelen P et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006 12 : 417 424.
8. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004 228 : 130 137.
9. Zhang QJ, Seipp RP, Chen SS, Vitalis TZ, Li XL, Choi KB, Jeffries A, Jefferies WA. TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma. Int J Cancer 2007 120 : 1935 1941.
10. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994 264 : 961 965. (Pubitemid 24196166)
11. Kundig TM, Bachmann MF, DiPaolo C et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995 268 : 1343 1347.
12. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996 17 : 131 137.
13. Ochsenbein AF, Sierro S, Odermatt B et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001 411 : 1058 1064.
14. Norbury CC, Sigal LJ. Cross priming or direct priming: is that really the question? Curr Opin Immunol 2003 15 : 82 8.
15. Blachere NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 2005 3 : e185.
16. Dolan BP, Gibbs KD Jr., Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 2006 177 : 6018 6024.
17. Zhang QJ, Li XL, Wang D et al. Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses. PLoS ONE 2008 3 : e3097.
18. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992 71 : 1093 1102.
19. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993 259 : 368 370.
20. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994 179 : 1205 1214.
21. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997 158 : 2834 2841.
22. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996 183 : 769 776.
23. Bacik I, Cox JH, Anderson R, Yewdell JW, Bennink JR. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J Immunol 1994 152 : 381 387.
24. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994 54 : 5552 5555.
25. Liu J, Xia X, Torrero M, Barrett R, Shillitoe EJ, Li S. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 2006 119 : 2113 2118.
26. Hallden G, Hill R, Wang Y et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003 8 : 412 424.
27. Nielsen LL, Gurnani M, Shi B, Terracina G, Johnson RC, Carroll J, Mathis JM, Hajian G. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics. Cancer Res 2000 60 : 7066 7074.
28. Garrigan K, Moroni-Rawson P, McMurray C, Hermans I, Abernethy N, Watson J, Ronchese F. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood 1996 88 : 3508 3512.
29. Greenberg PD, Klarnet JP, Kern DE, Cheever MA. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res 1988 32 : 104 127.
30. Levitsky HI. Tumors derived from antigen presenting cells. Semin Immunol 1996 8 : 281 287.
31. Alexander-Miller MA. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 2005 31 : 13 24.
32. Chambers CA, Gallinger S, Anderson SK, Giardina S, Ortaldo JR, Hozumi N, Roder J. Expression of the NK-TR gene is required for NK-like activity in human T cells. J Immunol 1994 152 : 2669 2674.
33. Mingari MC, Vitale C, Cambiaggi A, Schiavetti F, Melioli G, Ferrini S, Poggi A. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int Immunol 1995 7 : 697 703.
34. Ikeda H, Lethe B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997 6 : 199 208.
35. von Geldern M, Simm B, Braun M, Weiss EH, Schendel DJ, Falk CS. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I. Eur J Immunol 2006 36 : 2347 2358.
36. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992 255 : 1264 1266.
37. Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 1994 180 : 1415 1425.
38. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994 1 : 501 508.
39. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995 2 : 555 559.
40. Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellstrom I, Hellstrom KE, Marquardt H, Chen L. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med 1996 183 : 791 800.